Tolrestat Uses, Dosage, Side Effects and more
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.
| Attribute | Details |
|---|---|
| Trade Name | Tolrestat |
| Generic | Tolrestat |
| Tolrestat Other Names | Tolrestat |
| Type | |
| Formula | C16H14F3NO3S |
| Weight | Average: 357.347 Monoisotopic: 357.064648624 |
| Groups | Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the pharmacological control of certain diabetic complications.
Toxicity
Oral, mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50 = 980 mg/kg.
